The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion and analysis.
Some 20 months ago, I started having trouble sleeping. It had been almost two years since my colleagues and I had published a paper describing how a bacterial system called CRISPR–Cas9 could be used to engineer genomes.
I had been astounded at how quickly labs around the world had adopted the technology for applications across biology, from modifying plants to altering butterfly-wing patterns to fine-tuning rat models of human disease. At the same time, I’d avoided thinking too much about the philosophical and ethical ramifications of widely accessible tools for altering genomes.
Questions about whether genome editing should ever be used for non-medical enhancement, for example, seemed mired in subjectivity — a long way from the evidence-based work I am comfortable with. I told myself that bioethicists were better positioned to take the lead on such issues. Like everyone else, I wanted to get on with the science made possible by the technology.
Share this article
Yet as the uses of CRISPR–Cas9 to manipulate cells and organisms continued to mount, it seemed inevitable that researchers somewhere would test the technique in human eggs, sperm or embryos, with a view to creating heritable alterations in people. By the spring of 2014, I was regularly lying awake at night wondering whether I could justifiably stay out of an ethical storm that was brewing around a technology I had helped to create.
Read full, original post: Genome–editing revolution: My whirlwind year with CRISPR
